These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11036039)

  • 1. PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages.
    Martin M; Serradji N; Dereuddre-Bosquet N; Le Pavec G; Fichet G; Lamouri A; Heymans F; Godfroid JJ; Clayette P; Dormont D
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3150-4. PubMed ID: 11036039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
    Serradji N; Bensaid O; Martin M; Kan E; Dereuddre-Bosquet N; Redeuilh C; Huet J; Heymans F; Lamouri A; Clayette P; Dong CZ; Dormont D; Godfroid JJ
    J Med Chem; 2000 Jun; 43(11):2149-54. PubMed ID: 10841793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiretroviral ant anti-inflammatory properties of a novel platelet activation factor antagonist, PMS-601].
    Martin M; Serradji N; Dereuddre-Bosquet N; Bensaïd O; Fichet G; Lamouri A; Heymans F; Clayette P; Godfroid JJ; Dormont D
    Pathol Biol (Paris); 2000 Jun; 48(5):513-9. PubMed ID: 10949851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor.
    Lima RG; Moreira L; Paes-Leme J; Barreto-de-Souza V; Castro-Faria-Neto HC; Bozza PT; Bou-Habib DC
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):763-9. PubMed ID: 16910832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
    Serradji N; Martin M; Bensaid O; Cisternino S; Rousselle C; Dereuddre-Bosquet N; Huet J; Redeuilh C; Lamouri A; Dong CZ; Clayette P; Scherrmann JM; Dormont D; Heymans F
    J Med Chem; 2004 Dec; 47(25):6410-9. PubMed ID: 15566310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human immunodeficiency virus type 1 replication by combination of transcription inhibitor K-12 and other antiretroviral agents in acutely and chronically infected cells.
    Okamoto M; Okamoto T; Baba M
    Antimicrob Agents Chemother; 1999 Mar; 43(3):492-7. PubMed ID: 10049256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HIV replication and macrophage colony-stimulating factor production in human macrophages by antiretroviral agents.
    Kutza J; Fields K; Grimm TA; Clouse KA
    AIDS Res Hum Retroviruses; 2002 Jun; 18(9):619-25. PubMed ID: 12079557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell specific uptake of antiretroviral drugs: AZT coupled to LDL inhibits HIV replication in human macrophages.
    Mankertz J; von Baeyer H; Rokos K; Nündel M; Pauli G; Riedel E
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):85-8. PubMed ID: 7757316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of pregnancy steroid hormones and zidovudine in inhibition of HIV type 1 replication in monocytoid and placental Hofbauer cells: implications for the prevention of maternal-fetal transmission of HIV.
    Lee AW; Mitra D; Laurence J
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1235-42. PubMed ID: 9310291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine.
    Chiang G; Sassaroli M; Louie M; Chen H; Stecher VJ; Sperber K
    Clin Ther; 1996; 18(6):1080-92. PubMed ID: 9001825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
    Crowe SM; McGrath MS; Elbeik T; Kirihara J; Mills J
    J Med Virol; 1989 Nov; 29(3):176-80. PubMed ID: 2533247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of MS-8209, an amphotericin B derivative, on tumor necrosis factor alpha synthesis and human immunodeficiency virus replication in macrophages.
    Clayette P; Martin M; Beringue V; Dereuddre-Bosquet N; Adjou KT; Seman M; Dormont D
    Antimicrob Agents Chemother; 2000 Feb; 44(2):405-7. PubMed ID: 10639370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
    Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
    Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of azidothymidine and 9-(R)-2-(phosphono methoxypropyl)adenine.
    Franchetti P; Rossi L; Cappellacci L; Pasqualini M; Grifantini M; Balestra E; Forbici F; Perno CF; Serafini S; Magnani M
    Antivir Chem Chemother; 2001 May; 12(3):151-9. PubMed ID: 12959323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.
    Szebeni J; Wahl SM; Popovic M; Wahl LM; Gartner S; Fine RL; Skaleric U; Friedmann RM; Weinstein JN
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3842-6. PubMed ID: 2542948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis.
    Biancone L; Cantaluppi V; Boccellino M; Bussolati B; Del Sorbo L; Conaldi PG; Albini A; Toniolo A; Camussi G
    Am J Pathol; 1999 Nov; 155(5):1731-9. PubMed ID: 10550329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar coronary vascular effects in the rat perfused heart of platelet-activating factor structural analogues with agonist and antagonist properties.
    Man RY; Kinnaird AA
    Br J Pharmacol; 1995 Nov; 116(5):2359-64. PubMed ID: 8581269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-antibody conjugates with anti-HIV activity.
    Paulik M; Grieco P; Kim C; Maxeiner HG; Grunert HP; Zeichhardt H; Morré DM; Morré DJ
    Biochem Pharmacol; 1999 Dec; 58(11):1781-90. PubMed ID: 10571253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.
    Serradji N; Bensaid O; Martin M; Sallem W; Dereuddre-Bosquet N; Benmehdi H; Redeuilh C; Lamouri A; Dive G; Clayette P; Heymans F
    Bioorg Med Chem; 2006 Dec; 14(23):8109-25. PubMed ID: 16893650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection.
    Gross E; Amella CA; Pompucci L; Franchin G; Sherry B; Schmidtmayerova H
    J Leukoc Biol; 2003 Nov; 74(5):781-90. PubMed ID: 12960233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.